Clinical efficacy of restart immunotherapy for advanced hepatocellular carcinoma
10.3760/cma.j.cn115610-20211107-00547
- VernacularTitle:晚期肝细胞癌病人重启免疫治疗的临床疗效
- Author:
Qiang FU
1
;
Dongbo LIU
;
Qian SHEN
;
Mengxian ZHANG
;
Lihong ZHANG
;
Hong QIU
;
Xianglin YUAN
Author Information
1. 华中科技大学同济医学院附属同济医院肿瘤科，武汉 430030
- Keywords:
Liver neoplasms;
Immunotherapy;
Targeted therapy;
Corona virus disease 2019;
Restart immunotherapy;
Clinical efficacy
- From:
Chinese Journal of Digestive Surgery
2021;20(S2):45-48
- CountryChina
- Language:Chinese
-
Abstract:
China has a heavy burden of hepatocellular carcinoma, which is a serious threat to people′s life and health. However, the available drugs for advanced hepatocellular carcinoma in the past are limited and the efficacy is not satisfactory. In recent years, immunotherapy has a significant effects in some tumors. The authors introduce the efficacy of restart immunotherapy on an advanced hepatocellular carcinoma patient undergoing interruption of treatment due to corona virus disease 2019, in order to provide references for the diagnosis and treatment of this kind of patients.
